Obtustatin

200 1190 

Currency

Inhibitor of the binding of α1β1 integrin to collagen IV

Obtustatin is a 41 amino acid disintegrin peptide isolated from the venom of the Vipera lebetina obtusa. It is a potent (IC50 = 2 nM) and selective inhibitor of the binding of α1β1 integrin to collagen IV. Contrary to other known disintegrins, it does not contain the classical RGD sequence. Obtustatin does not show inhibitory activity toward other integrins, including α2β1, αIIbβ3, αvβ3, α4β1, α5β1, α6β1, and α9β1, α4β7 integrins. Obtustatin potently inhibits angiogenesis in chicken and in mouse model and reduces tumor development by half.

Contact us
SKU: 10OBT001 Category: Tag:

Description

AA sequence: Cys1-Thr-Thr-Gly-Pro-Cys6-Cys7-Arg-Gln-Cys10-Lys-Leu-Lys-Pro-Ala-Gly-Thr-Thr-Cys19-Trp-Lys-Thr-Ser-Leu-Thr-Ser-His-Tyr-Cys29-Thr-Gly-Lys-Ser-Cys34-Asp-Cys36-Pro-Leu-Tyr-Pro-Gly-OH
Disulfide bonds: Cys1-Cys10, Cys6-Cys29, Cys7-Cys34 and Cys19-Cys36
Length (aa): 41
Formula: C184H284N52O57S8
Molecular Weight: 4393.13 Da
Appearance: White lyophilized solid
Solubility: aqueous buffer
CAS number: not available
Source: Synthetic
Purity rate: > 97 %

Other desintegrin peptides from snake venoms have been discovered this past years containing RGD or non-RGD sequences. Desintegrins are promising compounds in cancer therapies or as anti-coagulant.

Contact us if you are looking for other desintegrin peptides.

Structural and dynamical properties of KTS-disintegrins: A comparison between Obtustatin and Lebestatin

Angiostatic activity of obtustatin as alpha1beta1 integrin inhibitor in experimental melanoma growth

KTS and RTS-disintegrins: anti-angiogenic viper venom peptides specifically targeting the alpha 1 beta 1 integrin

Amino acid sequence and homology modeling of obtustatin, a novel non-RGD-containing short disintegrin isolated from the venom of Vipera lebetina obtusa

Obtustatin: a potent selective inhibitor of alpha1beta1 integrin in vitro and angiogenesis in vivo

NMR solution structure of the non-RGD disintegrin obtustatin

Sign Up to our Newsletter

    Placeholder

    Obtustatin

    200 1190 Quote request